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Articles concluding that tight glycemic control (TGC) in the
intensive care unit (ICU) has no mortality benefit and an
unacceptably high rate of hypoglycemia have been published
recently in several journals. The Diabetes Special Interest
Group (DSIG) [1] believes that the data from some of these
recent papers have been interpreted incorrectly,
misconstrued, or misunderstood. The DSIG agrees with the
scientists whose editorial comments were published with
these articles [2,3] that the studies were underpowered to
show a lack of benefit and agrees that hypoglycemia below
40 mg/dL is an undesirable complication. The incidence of
hypoglycemia in these studies compares unfavorably with
data from results with the Glucommander, which in published
data has an overall hypoglycemia rate (below 40 mg/dL) of
only 2.6% [4], and more recently, no blood sugar below
40 mg/dL was seen in patients on the Glucommander in the
cardiovascular ICU [5]. Algorithms for achieving TGC are
being continually refined. The target ranges for ICU patients
are firmly established in only the post-cardiac surgical
population. The DSIG joins others in the hope that the NICE-
SUGAR (Normoglycemia in Intensive Care Evaluation -
Survival Using Glucose Algorithm Regulation) trial (currently in
the analysis phase, having enrolled over 6,000 subjects) will
add to the knowledge base for these issues and also notes
that the principal investigator for this study has commented
that even a negative finding for benefit will not provide
evidence in favor of abandoning glucose control entirely [6].
The DSIG has learned during its six-year effort that instituting
TGC is an individual institutional undertaking that first
requires broad commitment from, among others, both the
leadership and the implementing staff. Policies and protocols
specific to TGC are essential. Standardization is a must.
Chosen targets should be evidence-based and realistic for
the individual institution. Ongoing monitoring of outcomes,
including both the success rate for achieving the glycemic
target and the frequency of hypoglycemia, should guide
continuing education and protocol adjustments. Some
published protocols are more successful than others,
although there are no published randomized clinical trials to
clearly establish the best. Computerization of protocols with
alarms and reminders drastically reduces protocol violations
and calculation error and facilitates documentation. Achieving
TGC requires good protocols and reasonable targets, but
effective implementation at the institutional level (reflected by
consistent improvement in glycemic control) may be more
important than having the best protocol in safely achieving
the desired target range.
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